Loading...

PCC Rokita

WSE:PCR
Snowflake Description

Solid track record, good value and pays a dividend.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PCR
WSE
PLN2B
Market Cap
Add to portfolio
  1. Home
    2. ›
  2. PL
    3. ›
  3. Materials
Last updated 2019/04/17 23:17
Company description

PCC Rokita SA manufactures and distributes chemical products in Poland. The last earnings update was 30 days ago. More info.

Find similar companies

Add to Portfolio Compare Print
PCR Share Price and Events
7 Day Returns
5.2%
WSE:PCR
1.4%
PL Chemicals
-0.2%
PL Market
1 Year Returns
-11.2%
WSE:PCR
-16.7%
PL Chemicals
-2.2%
PL Market
PCR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PCC Rokita (PCR) 5.2% -2.1% 14.6% -11.2% 53.1% -
PL Chemicals 1.4% -5.7% 13.2% -16.7% -37.6% -16%
PL Market -0.2% -0.1% 1.3% -2.2% 12.4% -3.8%
1 Year Return vs Industry and Market
  • PCR outperformed the Chemicals industry which returned -16.7% over the past year.
  • PCR underperformed the Market in Poland which returned -2.2% over the past year.
Price Volatility
PCR
Industry
5yr Volatility vs Market
Related Companies

Value

 Is PCC Rokita undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of PCC Rokita to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for PCC Rokita.

WSE:PCR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.9%
Perpetual Growth Rate 10-Year PL Government Bond Rate 2.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for WSE:PCR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year PL Govt Bond Rate 2.9%
Equity Risk Premium S&P Global 7.1%
Chemicals Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.931 (1 + (1- 19%) (34.84%)) 		1.13
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)		 1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.85% + (1.13 * 7.14%) 		10.92%

Discounted Cash Flow Calculation for WSE:PCR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for PCC Rokita is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

WSE:PCR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (PLN, Millions) Source Present Value
Discounted (@ 10.92%)
2019 88.30 Analyst x1 79.61
2020 226.70 Analyst x1 184.26
2021 320.48 Est @ 41.37% 234.84
2022 416.02 Est @ 29.81% 274.84
2023 506.40 Est @ 21.72% 301.62
2024 587.73 Est @ 16.06% 315.60
2025 658.83 Est @ 12.1% 318.95
2026 720.26 Est @ 9.32% 314.36
2027 773.43 Est @ 7.38% 304.34
2028 820.00 Est @ 6.02% 290.90
Present value of next 10 years cash flows PLN2,619.32
WSE:PCR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= PLN820.00 × (1 + 2.85%) ÷ (10.92% – 2.85%) 		PLN10,451.53
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= PLN10,451.53 ÷ (1 + 10.92%)10 		PLN3,707.70
WSE:PCR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= PLN2,619.32 + PLN3,707.70 		PLN6,327.02
Equity Value per Share
(PLN)		 = Total value / Shares Outstanding
= PLN6,327.02 / 19.85 		PLN318.69
WSE:PCR Discount to Share Price
Calculation Result
Value per share (PLN) From above. PLN318.69
Current discount Discount to share price of PLN92.80
= -1 x (PLN92.80 - PLN318.69) / PLN318.69 		70.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price PCC Rokita is available for.
Intrinsic value
>50%
Share price is PLN92.8 vs Future cash flow value of PLN318.69
Current Discount Checks
For PCC Rokita to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • PCC Rokita's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • PCC Rokita's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PCC Rokita's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PCC Rokita's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
WSE:PCR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in PLN PLN11.42
WSE:PCR Share Price ** WSE (2019-04-17) in PLN PLN92.8
Poland Chemicals Industry PE Ratio Median Figure of 12 Publicly-Listed Chemicals Companies 14.18x
Poland Market PE Ratio Median Figure of 458 Publicly-Listed Companies 11.23x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PCC Rokita.

WSE:PCR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= WSE:PCR Share Price ÷ EPS (both in PLN)

= 92.8 ÷ 11.42

 8.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PCC Rokita is good value based on earnings compared to the PL Chemicals industry average.
  • PCC Rokita is good value based on earnings compared to the Poland market.
Price based on expected Growth
Does PCC Rokita's expected growth come at a high price?
Raw Data
WSE:PCR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 8.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts		 2.7%per year
Poland Chemicals Industry PEG Ratio Median Figure of 6 Publicly-Listed Chemicals Companies 0.76x
Poland Market PEG Ratio Median Figure of 114 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

WSE:PCR PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 8.12x ÷ 2.7%

 3.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PCC Rokita is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on PCC Rokita's assets?
Raw Data
WSE:PCR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in PLN PLN40.70
WSE:PCR Share Price * WSE (2019-04-17) in PLN PLN92.8
Poland Chemicals Industry PB Ratio Median Figure of 17 Publicly-Listed Chemicals Companies 0.64x
Poland Market PB Ratio Median Figure of 687 Publicly-Listed Companies 1.01x
WSE:PCR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= WSE:PCR Share Price ÷ Book Value per Share (both in PLN)

= 92.8 ÷ 40.70

 2.28x

* Primary Listing of PCC Rokita.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PCC Rokita is overvalued based on assets compared to the PL Chemicals industry average.
Show me more potentially undervalued companies in the Chemicals industry
X
Value checks
We assess PCC Rokita's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Chemicals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Chemicals industry average (and greater than 0)? (1 check)
    5. PCC Rokita has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is PCC Rokita expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is PCC Rokita expected to grow at an attractive rate?
  • PCC Rokita's earnings growth is positive but not above the low risk savings rate of 2.9%.
Growth vs Market Checks
  • PCC Rokita's earnings growth is positive but not above the Poland market average.
  • PCC Rokita's revenue growth is positive but not above the Poland market average.
Annual Growth Rates Comparison
Raw Data
WSE:PCR Future Growth Rates Data Sources
Data Point Source Value (per year)
WSE:PCR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 2.7%
WSE:PCR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 4.7%
Poland Chemicals Industry Earnings Growth Rate Market Cap Weighted Average 45.1%
Poland Chemicals Industry Revenue Growth Rate Market Cap Weighted Average 5%
Poland Market Earnings Growth Rate Market Cap Weighted Average 10.1%
Poland Market Revenue Growth Rate Market Cap Weighted Average 6.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
WSE:PCR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in PLN Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
WSE:PCR Future Estimates Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 1,637 239 1
2019-12-31 1,551 208 1
WSE:PCR Past Financials Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income *
2018-12-31 1,490 287 227
2018-09-30 1,445 254 243
2018-06-30 1,378 220 215
2018-03-31 1,345 181 213
2017-12-31 1,286 204 182
2017-09-30 1,234 264 208
2017-06-30 1,187 264 213
2017-03-31 1,129 259 207
2016-12-31 1,107 263 203
2016-09-30 1,084 220 135
2016-06-30 1,097 187 131
2016-03-31 1,077 161 110

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • PCC Rokita's earnings are expected to grow by 2.7% yearly, however this is not considered high growth (20% yearly).
  • PCC Rokita's revenue is expected to grow by 4.7% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
WSE:PCR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from PCC Rokita Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:PCR Future Estimates Data
Date (Data in PLN Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 12.02 12.02 12.02 1.00
2019-12-31 10.46 10.46 10.46 1.00
WSE:PCR Past Financials Data
Date (Data in PLN Millions) EPS *
2018-12-31 11.42
2018-09-30 12.23
2018-06-30 10.84
2018-03-31 10.71
2017-12-31 9.18
2017-09-30 10.46
2017-06-30 10.71
2017-03-31 10.41
2016-12-31 10.21
2016-09-30 6.82
2016-06-30 6.59
2016-03-31 5.52

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if PCC Rokita will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess PCC Rokita's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Poland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Poland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PCC Rokita has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has PCC Rokita performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PCC Rokita's growth in the last year to its industry (Chemicals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PCC Rokita has delivered over 20% year on year earnings growth in the past 5 years.
  • PCC Rokita's 1-year earnings growth is less than its 5-year average (24.4% vs 32.4%)
  • PCC Rokita's earnings growth has exceeded the PL Chemicals industry average in the past year (24.4% vs -27.5%).
Earnings and Revenue History
PCC Rokita's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PCC Rokita Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:PCR Past Revenue, Cash Flow and Net Income Data
Date (Data in PLN Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1,489.80 226.77 191.79
2018-09-30 1,445.43 242.77 195.91
2018-06-30 1,378.05 215.24 180.41
2018-03-31 1,344.59 212.57 174.30
2017-12-31 1,285.89 182.35 167.43
2017-09-30 1,234.12 207.73 160.78
2017-06-30 1,187.16 212.60 154.90
2017-03-31 1,129.27 206.70 151.73
2016-12-31 1,107.19 202.72 146.21
2016-09-30 1,084.32 135.47 142.63
2016-06-30 1,096.83 130.90 141.69
2016-03-31 1,076.51 109.51 133.43
2015-12-31 1,048.75 84.75 127.78
2015-09-30 1,052.94 73.02 131.08
2015-06-30 1,062.49 62.40 129.02
2015-03-31 1,083.30 61.73 128.66
2014-12-31 1,092.94 71.21 126.58
2014-09-30 1,065.66 58.30 119.04
2014-06-30 1,041.05 47.96 119.87
2014-03-31 1,084.77 52.42 123.07
2013-12-31 1,101.19 58.28 123.38
2013-09-30 1,156.87 231.70 122.86
2013-06-30 1,146.49 230.96 113.87
2013-03-31 1,098.14 274.25 107.15
2012-12-31 1,056.89 265.05 101.83
2012-09-30 995.90 110.82 105.13
2012-06-30 920.60 99.65 97.21

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • PCC Rokita has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • PCC Rokita used its assets more efficiently than the PL Chemicals industry average last year based on Return on Assets.
  • PCC Rokita has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Show me more strong past performing companies in the Chemicals industry
X
Past performance checks
We assess PCC Rokita's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Chemicals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PCC Rokita has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is PCC Rokita's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PCC Rokita's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PCC Rokita's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • PCC Rokita's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of PCC Rokita's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PCC Rokita Company Filings, last reported 3 months ago.

WSE:PCR Past Debt and Equity Data
Date (Data in PLN Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 808.01 641.92 57.30
2018-09-30 742.60 660.33 39.03
2018-06-30 689.39 680.56 46.15
2018-03-31 810.12 523.96 31.49
2017-12-31 746.67 482.38 72.33
2017-09-30 665.36 484.50 23.56
2017-06-30 639.80 467.32 31.72
2017-03-31 749.22 397.96 77.96
2016-12-31 715.39 415.24 145.48
2016-09-30 608.73 406.00 36.63
2016-06-30 578.15 413.00 34.45
2016-03-31 631.58 398.22 73.03
2015-12-31 601.86 386.06 84.53
2015-09-30 562.25 410.95 39.66
2015-06-30 536.35 407.16 32.07
2015-03-31 591.57 361.93 54.99
2014-12-31 586.47 362.69 121.96
2014-09-30 558.74 324.18 41.86
2014-06-30 543.44 290.16 35.76
2014-03-31 483.83 255.83 29.95
2013-12-31 532.43 260.09 50.46
2013-09-30 503.52 448.69 13.57
2013-06-30 512.48 239.01 52.18
2013-03-31 490.24 421.34 25.08
2012-12-31 523.31 226.39 57.71
2012-09-30 500.04 400.90 32.52
2012-06-30 493.48 233.28 20.00
  • PCC Rokita's level of debt (79.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (48.9% vs 79.4% today).
  • Debt is well covered by operating cash flow (44.7%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 14.5x coverage).
X
Financial health checks
We assess PCC Rokita's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
    7. PCC Rokita has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is PCC Rokita's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
8.95%
Current annual income from PCC Rokita dividends. Estimated to be 9.43% next year.
If you bought PLN2,000 of PCC Rokita shares you are expected to receive PLN179 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • PCC Rokita's pays a higher dividend yield than the bottom 25% of dividend payers in Poland (2.74%).
  • PCC Rokita's dividend is above the markets top 25% of dividend payers in Poland (7.56%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
WSE:PCR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Poland Chemicals Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 6.4%
Poland Market Average Dividend Yield Market Cap Weighted Average of 207 Stocks 3.3%
Poland Minimum Threshold Dividend Yield 10th Percentile 1.3%
Poland Bottom 25% Dividend Yield 25th Percentile 2.7%
Poland Top 25% Dividend Yield 75th Percentile 7.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

WSE:PCR Future Dividends Estimate Data
Date (Data in PLN) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 9.00 1.00
2019-12-31 8.50 1.00
WSE:PCR Past Annualized Dividends Data
Date (Data in PLN) Dividend per share (annual) Avg. Yield (%)
2018-05-16 8.310 9.068
2018-03-08 8.310 7.517
2017-05-11 7.560 7.911
2017-03-07 7.560 8.787
2017-01-16 7.560 11.253
2016-05-12 4.480 7.175
2016-03-16 4.480 7.836
2015-05-12 3.490 8.300
2015-03-18 3.490 8.167
2015-01-15 3.490 9.167
2014-06-25 8.640 25.445

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PCC Rokita has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • PCC Rokita has only been paying a dividend for 5 years, and since then dividends per share have fallen.
Current Payout to shareholders
What portion of PCC Rokita's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.4x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.3x coverage).
Show me more dividend paying companies in the Chemicals industry
X
Income/ dividend checks
We assess PCC Rokita's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PCC Rokita afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
    7. PCC Rokita has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of PCC Rokita's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Wieslaw Klimkowski
COMPENSATION PLN1,346,498
CEO Bio

Mr. Wieslaw Klimkowski serves as the President of the Management Boards at Rokita S.A. and Silesia-Kalk Sp. z o.o. Mr. Klimkowski serves as President of the Management Board and Director of Investor Supervision & Group Development of PCC Rokita SA. He has been Chief Executive Officer of PCC Rokita S.A since 2010. He served as Project Manager at PCC Rokita S.A. from 1999 to 2002. He served as a Member of the Management Board of Rokita S.A. from 2005 to 2010. He served as Director of PCC Rokita SA. He serves as Member of Supervisory Board at PCC Exol Spólka Akcyjna. He serves as Member of the Supervisory Boards of: Chemi-Progress Polska Sp. z o.o., Zaklad Budowy Aparatury „Apakor-Rokita” Sp. z o.o., PCC Autochem Sp. z o. o., BiznesPark Rokita Sp. z o.o., PCC Chlor- Alkali Sp. z o.o., Centrum Wspierania Biznesu „Partner” Sp. z o.o., Zaklad Chemii Gospodarczej i Samochodowej „Kosmet-Rokita” Sp. z o.o., Biuro Projektowo Inzynieryjne „Technochem” Sp. z o.o., Tensis Sp. z o.o., Polskie Centrum Teleinformatyki S.A., PCC Consumer Products Sp. z o.o., Kosmet Sp. z o.o., Chemi-Plan S.A., and Przedsiebiorstwo Inzynierii i Ochrony Srodowiska „Gekon” SA w likwidacji. Mr. Klimkowski holds a degree in Law and in Economics from the University of Wroclaw.

CEO Compensation
  • Wieslaw's compensation has increased by more than 20% in the past year.
  • Wieslaw's remuneration is higher than average for companies of similar size in Poland.
Management Team

Robert Pabich

TITLE
Secretary of the Supervisory Board & Member of Supervisory Board
COMPENSATION
PLN48K

Wieslaw Klimkowski

TITLE
President of the Mgmt Board
COMPENSATION
PLN1M

Rafal Zdon

TITLE
VP of the Management Board & Financial Director
COMPENSATION
PLN1M
TENURE
9.3 yrs

Marcin Suchanek

TITLE
Acting MD of the Energy Business Unit & Purchasing Director
Board of Directors

Alfred Pelzer

TITLE
Chairman of the Supervisory Board
AGE
58

Waldemar Preussner

TITLE
Deputy Chairman of Supervisory Board
AGE
58

Robert Pabich

TITLE
Secretary of the Supervisory Board & Member of Supervisory Board
COMPENSATION
PLN48K
TENURE
3.1 yrs

Mariusz Dopierala

TITLE
Member of Supervisory Board
COMPENSATION
PLN46K

Arkadiusz Szymanek

TITLE
Member of Supervisory Board
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (PLN) Value (PLN)
X
Management checks
We assess PCC Rokita's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
    5. PCC Rokita has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

PCC Rokita SA (WSE:PCR) Delivered A Better ROE Than Its Industry

This article is for those who would like to learn about Return On Equity (ROE). … One way to conceptualize this, is that for each PLN1 of shareholders' equity it has, the company made PLN0.28 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St - –

Did Changing Sentiment Drive PCC Rokita's (WSE:PCR) Share Price Down By -70%?

For example, PCC Rokita SA (WSE:PCR) shareholders have seen the share price rise 70% over three years, well in excess of the market return (14%, not including dividends). … During three years of share price growth, PCC Rokita achieved compound earnings per share growth of 39% per year. … The average annual share price increase of 19% is actually lower than the EPS growth.

Simply Wall St - –

What You Must Know About PCC Rokita SA's (WSE:PCR) Financial Strength

However, an important fact which most ignore is: how financially healthy is the business? … Evaluating financial health as part of your investment thesis is. … Here are few basic financial health checks you should consider before taking the plunge.

Simply Wall St - –

Here's What PCC Rokita SA's (WSE:PCR) P/E Ratio Is Telling Us

The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). … PCC Rokita has a price to earnings ratio of 7.69, based on the last twelve months. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St - –

How Does PCC Rokita SA (WSE:PCR) Fare As A Dividend Stock?

A large part of investment returns can be generated by dividend-paying stock given their role in compounding returns over time. … Historically, PCC Rokita SA (WSE:PCR) has paid dividends to shareholders, and these days it yields 9.6%. … Participate in a short research study and receive a 6-month subscription to the award winning Simply Wall St research tool (valued at $60)

Simply Wall St - –

PCC Rokita SA (WSE:PCR) Earns A Nice Return On Capital Employed

Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. … Return On Capital Employed (ROCE): What is it? … ROCE measures the 'return' (pre-tax profit) a company generates from capital employed in its business.

Simply Wall St - –

Can PCC Rokita SA (WSE:PCR) Maintain Its Strong Returns?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Another way to think of that is that for every PLN1 worth of equity in the company, it was able to earn PLN0.33. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St - –

How PCC Rokita SA (WSE:PCR) Could Add Value To Your Portfolio

Building up an investment case requires looking at a stock holistically. … Today I've chosen to put the spotlight on PCC Rokita SA (WSE:PCR) due to its excellent fundamentals in more than one area.

Simply Wall St - –

What does PCC Rokita SA's (WSE:PCR) Balance Sheet Tell Us About Its Future?

While small-cap stocks, such as PCC Rokita SA (WSE:PCR) with its market cap of zł1.6b, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Assessing first and foremost the financial health is. … Here are a few basic checks that are good enough to have a broad overview of the company’s financial strength.

Simply Wall St - –

Is PCC Rokita SA's (WSE:PCR) P/E Ratio Really That Good?

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … PCC Rokita has a price to earnings ratio of 7.71, based on the last twelve months. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St - –

Company Info

Description

PCC Rokita SA manufactures and distributes chemical products in Poland. The company offers chloralkali, raw materials, and intermediates; polyurethanes, including flame retardants, poliurethane systems, and polyether polyols; specialty products consisting formulations, lubricants and functional fluids, and specialty additives; and surfactants, including amphoteric, anionic, cationic, and non-ionic surfactants. It serves adhesives, agrochemicals, building and construction, case, detergents, fire prevention, food and fuel industry, furniture, I&I cleaning, lubricants and functional fluids, metallurgical, mining and drilling, oilfield, paints and coatings, personal care, pharmaceuticals, plastics, power, printing ink, pulp and paper, raw materials and intermediates, refrigeration and household appliances, sports and recreation, tanning and textile, transportation, and water and wastewater treatment industries. The company is based in Brzeg Dolny, Poland. PCC Rokita SA is a subsidiary of PCC SE.

Details
Name: PCC Rokita SA
PCR
Exchange: WSE
Founded:
PLN1,842,386,240
19,853,300
Website: http://www.pcc.rokita.pl
Address: PCC Rokita SA
ul. Sienkiewicza 4,
Brzeg Dolny,
56-120,
Poland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
WSE PCR Bearer Shares Warsaw Stock Exchange PL PLN 25. Jun 2014
LSE 0QVX Bearer Shares London Stock Exchange GB PLN 25. Jun 2014
Number of employees
Current staff
Staff numbers
0
PCC Rokita employees.
Industry
Specialty Chemicals
Materials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 23:17
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/03/20
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Related Companies

© 2019 Simply Wall Street Pty Ltd, Community Design 2845206, US Design Patent #29/544/281, European Design Registration #2845206, Standard & Poor’s Financial Services LLC. All rights reserved.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2019, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2019)